Abstract 2199: BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development

Authors: Mitchell Keegan, Keith Wilcoxen, Peter T. Ho

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-2199

Source: Full article

---

Abstract

Abstract